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Tumor-associated macrophages (TAMs) have been shown to be associated with poor prognosis 25 
of cancer and are predominately localized in the hypoxia regions of tumor. We demonstrated in 26 
this study that hypoxia increases the synthesis and secretion of galectin-3 by TAMs. The 27 
increased expression of galectin-3 in TAMs was seen to be associated with nucleation of 28 
transcription factor NF-κB through generation and activation of ROS and promoted tumor 29 
growth and metastasis in vitro and in mice through multiple molecular mechanisms. It was 30 
found that the TAMs-mediated promotion of tumor growth and metastasis in hypoxia was 31 
inhibited by administration of macrophage-depletion agent clodronate liposomal (CL) or 32 
galectin-3 inhibitor modified citric pectin (MCP) in orthotopic syngeneic mammary 33 
adenocarcinoma model and metastasis model. Co-administration of anti-angiogenesis agent 34 
sorafenib or bevacizumab with CL and MCP showed to cause stronger inhibition of tumor 35 
growth and metastasis than administration of each agent alone. These results indicate that 36 
hypoxia-induced galectin-3 expression and secretion from TAMs promotes tumor growth and 37 
metastasis. Targeting the actions of galectin-3 in hypoxia may be a potential therapeutic strategy 38 
for cancer treatment. 39 
 40 





1. Introduction 43 
The presence of large quantities of tumor-associated macrophages (TAMs) in cancer is often 44 
associated with increased levels of tumor angiogenesis, metastasis and poor prognosis[1]. 45 
TAMs are frequently seen in the hypoxic regions of the tumors where they have been speculated 46 
to acquire and exert tumor-promoting actions[2].    47 
Galectin-3 is a family member of the β-galactoside binding proteins which share similar 48 
carbohydrate-recognition domains. It is a multifunctional protein and is involved in many 49 
aspects of macrophage activity, such as migration, apoptosis, phagocytosis, and adhesion[3] [4-50 
6]. Galectin-3 is expressed in the cytoplasm and nucleus and is also secreted outside the cells[7, 51 
8]. Intracellular galectin-3 participates in cell proliferation, differentiation, and apoptosis while 52 
extracellular galectin-3 mediates cell-cell and cell-environment interactions. Expression of 53 
galectin-3 is commonly increased in inflammation, cancer and a few other diseases such as 54 
heart failure and is closely involved in tumor cell transformation, migration, invasion and 55 
metastasis[8-10]. 56 
Galectin-3 is known to be secreted by epithelial and immune cells[11, 12] and its expression 57 
has been reported to be particularly high in the hypoxic regions in breast, lung and prostate 58 
cancer[4-6]. However, the relationship between galectin-3 and hypoxic TAMs, and the impact 59 
of this relationship on the tumor development and metastasis are unclear. It was found in this 60 
study that galectin-3 expression and secretion was significantly increased in TAMs in hypoxia 61 
and promoted cancer cell migration and invasion in vitro and TAMs-mediated metastasis in vivo 62 






2. Materials and methods  66 
2.1 Reagents 67 
β-lactose and metformin were purchased from Sigma (Darmstadt, Germany). MCP was 68 
purchased from Econugenics (Santa Rosa, USA). Compound C, AICAR, Ly294002 and 2ME2 69 
were the products of Selleck (Shanghai, China). PDTC, NAC and rosup were purchased from 70 
Beyotime (Haimen, China). Sorafenib was purchased from Hiboled century biotechnology 71 
(Shenzhen, China). Liposomal clodronate was purchased from YEASEN (Amsterdam, 72 
Netherlands). Bevacizumab was purchased from Roche (Basel, Switzerland). 73 
2.2 Cell lines 74 
Human monocyte (THP-1), Human breast cancer cell line (MDA-MB-231),  Human 75 
umbilical vein endothelial cells (HUVECs) were obtained from Type Culture Collection of the 76 
Chinese Academy of Sciences, Shanghai, China. Luciferase-labeled  MDA-MB-231 cells 77 
(MDA-MB-231-luc cells) and 4T1cells (4T1-luc cells) which were kindly provided by Caliper 78 
Life Sciences, Inc (Hopkinton, MA, USA). All cells were cultured in RPMI-1640medium 79 
supplemented with 10% fetal bovine serum (Gibico, CA, USA) at 37 °C, 5% CO2. 80 
2.3 Preparation of condition medium 81 
Cells were cultured in serum-free 1640 medium for 48 h. The culture medium was collected 82 
and centrifuged at 1000×g for 5 min. The supernatant was taken as initial condition medium 83 
(iCM). Thirty percent (v/v) fresh complete medium was added to iCM prior to the experiments 84 
to replenish the consumption of nutrition to obtain the final CM. 85 
2.4 Preparation of M2 phenotype macrophage (M2) or TAMs 86 




24-well plates were treated with 320 nM PMA (Sigma, Darmstadt, Germany) for 24 h at 37°C, 88 
followed by incubation with 20 ng/mL IL-4 (Petprotec, RockyHill, NJ) and 20 ng/mL IL-13 89 
(Petprotec, RockyHill, NJ) for an additional 72 h at 37°C to obtain M2 type macrophages. 90 
For the preparation of TAMs, THP-1 cells (1×105 cells per well) seeded in 24-well plates 91 
were treated with 320 nM PMA for 24 h at 37°C, followed by incubation with CM of MDA-92 
MB-231 cells for an additional 72 h at 37°C. 93 
2.5 Establishment of hypoxia model 94 
Chemical hypoxia cellular model was established by added chemical regent Na2S2O4 at 1~8 95 
mM (Sigma, Darmstadt, Germany) into the medium for 1 h before other treatment on cells. 96 
Physical hypoxia model was accomplished by using hypoxia chambers. The hypoxia chamber 97 
used for the cell experiments is the ProOX C21 and for animal experiments is ProOX 360 of 98 
BioSpherix Ltd. (Redfield, NY, USA). 99 
2.6 Identification of M2 or TAMs by flow cytometry 100 
The above prepared macrophages were collected with a scraper and blocked with 3% BSA 101 
for 45 min, and then were incubated with PE-conjugated anti-human CD163 antibodies (333605; 102 
Biolegend, California, USA) for 45 min or FITC-conjugated anti-human CD68 antibodies 103 
(333805; Biolegend, California, USA) according to the manufacturers’ instructions. At least 104 
1×104 cells of each sample were analyzed using the BD FACS Calibur cytometer (Becton 105 
Dickinson, CA, USA). 106 
2.7 Cell transfection 107 
Cell transfections were carried out with the Micropoly-transfecter Cell Reagent (Micropoly, 108 
Shanghai, China) according to the manufacturer’s instructions. The coding strand targeting by 109 




control siRNA was 5’- TTC TCC GAA CGT GCT GTC TTT-3’. 111 
2.8 In vitro angiogenesis assay 112 
One hundred microliter Matrigel (BD Biosciences, MA, USA) was added into pre-cooled 113 
96-well plates on ice and incubated for 30 min at 37 °C. HUVECs (3 × 104 cells per well) were 114 
added into the 96-well plate and cultured with 100 μL CM for 6 h at 37 °C before visualization 115 
and image under a light microscope. Photographs were captured with a Nikon inverted 116 
microscope (Nikon, Tokyo, Japan), and the length of tubes was counted and analyzed. 117 
2.9 In vitro vascular mimicry assay 118 
Nanty-six-well plates were precoated with 100 μL BD Matrigel. MDA-MB-231 cells (3 × 104 119 
cells per well) were added and cultured with 100 μL CM for 6 h at 37 °C. Tube formation of 120 
vascular mimicry was visualized under a light microscope. Photographs were captured with a 121 
Nikon inverted microscope (Nikon, Tokyo, Japan), and the length of tubes was counted and 122 
analyzed. 123 
2.10 MTT assay 124 
Cell proliferation was determined by 3-(4,5-Dimethylthiazol-2-yl)-2,5- diphenyltetrazolium 125 
bromide (MTT; Solarbio, Beijing, China) assay. The cells (4 × 103 cells per well) were seeded 126 
on 96-well plates and cultured for 24 h, then 100 μL of CM of TAMs was added and incubated 127 
for 48 h before 20 μL of MTT solution (5 mg/mL in phosphate buffered saline; PBS) was added 128 
for further 4 h. The medium was removed and replaced with 150 μL of DMSO to dissolve the 129 
formazan crystal. The absorbance was measured at 570 nm using Thermo Multiskan GO 130 
microplate reader (Thermo-1510, CA, USA). 131 




THP-1 cells (1×105cells per well) seeded in 24-well plates were differentiated into M2 or 133 
TAMs as described above. For invasion assay, the upper chamber was first coated with Matrigel. 134 
For migration assay, no Matrigel was added to the upper chamber. MDA-MB-231 cells were 135 
delivered into the upper compartment of transwell chamber (Corning, NY, USA) and co-136 
cultured with TAMs in the lower compartment. After 48h, the cells remained on the upper 137 
surface of the transwell chamber were removed by cotton swabs. Cells on the bottom side of 138 
the transwell chamber were fixed by cold methanol-glacial acetic acid and stained with crystal 139 
violet, and counted. 140 
2.12 Western blot analysis 141 
The cells were lysed in RIPA buffer and the protein concentration was determined with the 142 
BCA protein assay. Equal amounts of protein were separated by sodium dodecyl sulphate 143 
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto a polyvinylidene fluoride 144 
(PVDF) membrane (Millipore, Billerica, USA). The membranes were washed, blocked with 145 
TBST buffer (20 mM Tris-buffered saline and 0.1% Tween-20) containing 5% (w/v) nonfat dry 146 
milk overnight before incubated with antibodies against human PI3K (#4255), HIF-1α (#36169), 147 
NF-κB (#4764) p-AMPK (#2537, Cell Signaling Technology, CST, Boston, MA, USA), AMPK 148 
(10929-2-AP, Proteintech, Wuhan, China) and anti-β-actin (ZF-0313, ZS Bio. Beijing, China). 149 
The secondary antibodies used were either goat anti-mouse or goat anti-rabbit IgG (PIERCE, 150 
1:10000 in TBST), depending on the primary antibody. Antibody bindings were detected by 151 
enhanced chemiluminescence reagent and quantified by densitometry using a ChemiDoc XRS 152 
+ molecular imager (Bio-Rad, CA, USA). 153 
2.13 Quantitative real-time PCR 154 




USA) following the manufacturer’s instructions. First-strand cDNA was produced from total 156 
RNA by using a qPCR RT Kit (Toyobo, Osaka, Japan), according to manufacturer’s instructions. 157 
Samples were cycled for 30 s at 95°C, 30 s at 59°C and 30 s for 72°C for 40 cycles. QRT-PCR 158 
of the mRNA was performed on a LightCycler480 II real-time PCR system (Roche, Basel, 159 
Switzerland), using the SYBR-Green Chemistry (Toyobo, Osaka, Japan). Detail information of 160 
the primers sequences as below: galectin-3 sequence (5’-3’): 161 
ATGCAAACAGAATTGCTTTAG ATT; IL-10 sequence (5’-3’): 162 
TCTCCGAGATGCCTTCAGCAGA; IL-12 sequence (5’-3’): 163 
GACATTCTGCGTTCAGGTCCAG; NOS2sequence (5’-3’): GCTCTAC 164 
ACCTCCAATGTGACC. 165 
2.14 Immunofluorescence staining 166 
THP-1 cells (1×105 cells per well) seeded in 24-well plates with a coverslip/well were 167 
differentiated as described above. The cells were fixed in 4% paraformaldehyde in PBS at room 168 
temperature for 20 min, and permeabilized for 30 min in PBS containing 0.2% Triton X-100 169 
(Beyotime, Haimen, China), 10% BSA (Sigma, Darmstadt, Germany) and primary antibodies 170 
at 4°C overnight. Then cells were washed three times with PBST and incubated at room 171 
temperature for 1 h with anti-rabbit or anti-mouse secondary antibodies. Finally, cells were 172 
labeled with Hoechst 33342 to stain the nucleus, and fluorescence images were taken with 173 
fluorescence microscope (NIKON Ti-U, Nikon, Japan). 174 
2.15 ELISA  175 
After transfection with siGal-3, the cells were cultured in serum-free 1640 medium for 24 h. 176 
The supernatant of the culture medium was collected, centrifuged at 1000× g for 5 min, and 177 




using Quantikine ELISA kits (R&D Systems, MN, USA) according to the manufacturer’s 179 
instructions. 180 
2.16 Glucose consumption assay 181 
Glucose level in culture medium supernatant of TAMs was detected using Glucose Assay Kit 182 
(Nanjing Jiancheng Bioengineering Institute, Nanjing, China). Glucose intake by TAMs is 183 
equal to the amount of glucose in fresh medium minus the amount of glucose in the supernatant 184 
of treatment group. Cells were collected and the number of cells was counted by cell counter. 185 
The values of glucose level were normalized to the number of cells.  186 
2.17 Mouse metastasis model and IVIS imaging  187 
Five‐week‐old female Balb/c mice and Balb/c nude mice were purchased from the Animal 188 
Center of China Academy of Medical Science (Beijing, China) and housed under pathogen‐189 
free conditions. All animal experiment protocols were conducted in strict accordance with the 190 
Institutional Guidelines of Animal Care and Use Committee of Shandong University. 191 
In the 4T1-luc orthotopic syngeneic tumor mouse model, fifty Balb/c mice were injected with 192 
5 ×105 4T1-luc cells into the mammary fat pad under #3 mammary gland. Once the tumor 193 
volume reached 100 ~ 200 mm3, over-or under-sized mice were excluded. There remaining 194 
mice were divided randomly into four groups (n = 5) for effect of galectin-3 inhibitor MCP or 195 
CL (to induce monocyte depletion) on orthotopic growth of breast cancer in hypoxia: normaxia 196 
control (normal saline, i.g.); hypoxia control (8% O2 condition 6 h/day); hypoxia (8% O2 197 
condition 6 h/day) + MCP (0.5 μL/g/day, i.t.); hypoxia (8% O2 condition 6 h/day) + CL (10 198 
μL/g/week, i.v.). Other remaining mice were randomly divided into four groups for effect of 199 
bevacizumab and MCP on orthotopic growth of breast cancer: control (normal saline, i.g.); 200 




bevacizumab (5 mg/kg/week, i.v.). The body weight and tumor volume of all animals were 202 
measured every 3 days. V = L×W2/2 and was used to calculate the tumor volume (V), in which 203 
W refers to the short axis and L refers to the long axis. 204 
In the metastasis model: nude mice were intravenous injected with 1×105 MDA-MB-231-luc 205 
cells by tail vein. Mice were randomly divided into five groups (n = 5): control; metastasis 206 
model (normal saline, i.g.); sorafenib (15 mg/kg/day, i.g.); CL (10 μL/g/week, i.v.); sorafenib 207 
(15 mg/kg/day, i.g.) + CL (10 μL/g/week, i.v.). The body weights of all of the animals were 208 
measured every 3 days.  209 
The mice were anesthetized by isoflurane and imaged using the IVIS Kinetic in vivo imaging 210 
system (Caliper Life Sciences, MA, USA) at nine minutes after injecting D-luciferin potassium 211 
salt intraperitoneally every 7 days for up to 21 days. At the end of the experiment, the mice 212 
were sacrificed, and the xenografts and lungs were removed and weighed. 213 
2.18 Immunohistochemical assay 214 
Tumors or lung tissues of the metastasis mice were dissected and directly embedded in O.C.T. 215 
compound. Sections were cut and fixed with cold 4% paraformaldehyde, immunostained with 216 
mouse anti-galectin-3 (1:200; 60207-1, Proteintech, Wuhan, China), rabbit anti-CD31 (1:100; 217 
#3529, CST, Boston, MA), rabbit anti-CD68 (1:50, #76437, CST, Boston, MA) and 218 
Hypoxyprobe-1 (1:100;  Hypoxyprobe Inc., Burlington, MA) antibodies. Rabbit anti-mouse 219 
rhodamine antibody (1:200; Santa Cruz, CA, USA) or rabbit anti- mouse FITC antibody (1:200; 220 
Santa Cruz, CA, USA) were applied as secondary antibodies. Sections were incubated with 221 
DAPI (Solarbio, Beijing, China) for 5 min at room temperature. The immunofluorescence 222 
intensity was observed by fluorescence microscope (NIKON Ti-U, Nikon, Japan). 223 




All quantitative data are expressed as mean ± SD. Multiple comparisons were performed by 225 
one-way analysis of variance (one-way ANOVA). A P-value < 0.05 was considered statistically 226 
significant. Statistical analysis was performed using the SPSS/Win 13.0 software. 227 
 228 
3. Results 229 
3.1 TAMs promote proliferation, invasion and migration of MDA-MB-231 cells, and 230 
angiogenesis of HUVECs under hypoxia 231 
Human monocyte cell line THP-1 is widely used as a model for monocyte/macrophages 232 
differentiation. M2-polarised macrophages (M2) were obtained from THP-1 cells after 233 
treatment with IL-4 and IL-13. TAMs were obtained from incubation of THP-1 cells with 234 
conditioned cell culture medium (CM) from human breast cancer MDA-MB-231 cells. As 235 
shown in Fig. 1A, the resulting TAMs exhibited a significantly higher level of M2-specific cell-236 
surface markers CD68 and CD163 compared with THP-1 cells. At mRNA level, the expressions 237 
of M2 markers, IL-1Rα and IL-10, were both significantly upregulated while the expression of 238 
M1 macrophage markers NOS2 and IL-12 were both downregulated in the TAMs (Fig. 1B). 239 
These confirm the successful differentiation of THP-1 monocytes into M2-polarized TAMs by 240 
CM of MDA-MB-231 cells.  241 
Treatment with CM of both M2 and TAMs showed to have increased the ability of HUVECs 242 
to form micro-tube structures in hypoxia (Fig. 1C), and also increased MDA-MB-231 cells 243 
proliferation (Fig. 1D). Co-culture of M2 or TAMs with MDA-MB-231 cells also enhanced 244 
MDA-MB-231 cell migration and invasion in trans-wells under hypoxia (Fig. 1E). These 245 
findings suggest that the presence of TAMs promotes proliferation, invasion and migration of 246 





3.2 Hypoxia induces the expression and secretion of galectin-3 by TAMs 249 
Under hypoxia conditions of either culturing cells in hypoxic chambers (1% O2) or by 250 
exposing cells to sodium dithionite (Na2S2O4), the expression of galectin-3 in M2 and TAMs at 251 
protein (Fig. 2A) and mRNA levels (Fig. 2B), as well as galectin-3 secretion (Fig. 2C) by M2 252 
or TAMs, were all significantly increased in hypoxic degree- and time-dependent manners. A 253 
general increase of galectin-3 translocation from the cytoplasm to the nucleus in TAMs was 254 
also observed under hypoxia (Fig. 2D). In the 4T1-luc orthotopic syngeneic breast cancer 255 
mouse model, galectin-3 was seen to be highly expressed in the hypoxic (hypoxiprobe-1 256 
positive) regions in the tumor (Fig. 2E). These findings indicate that hypoxia induces TAMs 257 
expression and secretion of galectin-3. 258 
 259 
3.3 TAMs-mediated expression and secretion of galectin-3 under hypoxia promote 260 
migration/invasion of breast cancer cells 261 
To determine the role of the increased galectin-3 secretion by TAMs or increased expression 262 
of galectin-3 in TAMs in TAMs-mediated promotion of tumor cell migration and invasion, the 263 
migration and invasion of MDA-MB-231 cells were assessed by siRNA (siGal-3)  galectin-3 264 
suppression in TAMs and the presence of galectin-3 binding inhibitor, β-lactose. Suppression 265 
of galectin-3 expression by siGal-3 in M2 or TAMs or treatment with β-lactose of M2 (Fig. 3A) 266 
or TAMs (Fig. 3B) reduced migration and invasion of MDA-MB-231 cell in hypoxia in co-267 
culture of M2 or TAMs with MDA-MB-231 cells. The presence of modified citric pectin (MCP), 268 
another galectin-3 inhibitor, in the co-culture also reduced TAMs-mediated promotion of MDA-269 




MDA-MB-231 cell migration and invasion was lower in normoxia than that in hypoxia (Fig. 271 
3D). In addition, suppression of galectin-3 by siGal-3 in M2 or TAMs obviously reduced the 272 
proliferation of MDA-MB-231 cells by incubation with CM of M2 or TAMs in hypoxia in 273 
comparison to scramble siRNA control group (Fig. 3E), which suggest that the hypoxia-induced 274 
galectin-3 in TAMs may also be involved in the promotion of MDA-MB-231 cells proliferation. 275 
These results indicate that under hypoxia, TAMs-associated galectin-3 expression and secretion 276 
of galectin-3 are both involved in TAMs-mediated promotion of tumor cell proliferation and 277 
migration/invasion. 278 
Moreover, suppression of galectin-3 expression by siGal-3 in M2 or TAMs caused a 279 
reduction of cell survival with the inhibition rate of 9.6 % or 8.57 %, respectively (Fig. 3F), 280 
which indicated that the inhibition of TAMs survival had a limited contribution to the inhibitory 281 
effects of siGal-3 on the migration/invasion of MDA-MB-231 cells. Suppression of galectin-3 282 
expression caused a significant reduction on glucose consumption of M2 or TAMs in hypoxia 283 
(Fig. 3G). The ELISA result showed that suppression of intracellular galectin-3 expression also 284 
decreased the secretion of galectin-3 (Fig. 3H) and vascular endothelial growth factor A 285 
(VEGFA) (Fig. 3I) from both M2 and TAMs. These results indicate that an increased uptake of 286 
glucose and increase of VEGFA secretion by TAMs, caused by hypoxia-induced expression of 287 
galectin-3 in TAMs, may contribute to TAMs-mediated promotion of angiogenesis. 288 
 289 
3.4 Galectin-3 secretion by TAMs promotes angiogenesis and vascular mimicry under 290 
hypoxia 291 
To investigate whether galectin-3 expression and secretion by TAMs were involved in TAMs-292 




was assessed with and without galectin-3 suppression and in the presence or absence of lactose 294 
under hypoxia. Suppression of galectin-3 expression in TAMs or presence of lactose resulted 295 
in significant increase of VM formation of MDA-MB-231 cells as well as significant increase 296 
of HUVECs tube formation (Fig. 4A and 4B). The presence of lactose and siRNA galectin-3 297 
knockdown in combination showed to cause a bigger effect than the presence of lactose or 298 
galectin-3 knockdown alone. The siGal-3 in TAMs also showed a similar inhibitory effect to 299 
tube formation and VM formation in normoxia but to a less degree than under hypoxia (Fig. 300 
4C). Treatment of the cells with MCP reduced the pro-angiogenesis effects of TAMs (Fig. 4D). 301 
A less inhibitory effect on HUVECs proliferation was observed from CM of TAMs treated with 302 
siGal-3 than the scramble siRNA control group and this inhibitory effect of siGal-3 occurred 303 
less in normoxia than in hypoxia (Fig. 4E). siGal-3 or β-lactose, alone or in combination, 304 
inhibited invasion and migration of HUVECs co-cultured with TAMs in hypoxia (Fig. 4F). 305 
These indicate that both intracellular and extracellular galectin-3 in hypoxic TAMs are involved 306 
in TAMs-mediated promotion of angiogenesis. 307 
 308 
3.5 Upregulation of galectin-3 in TAMs under hypoxia is dependent on NF-κB via ROS 309 
To investigate the mechanism of galectin-3 upregulation in TAMs under hypoxia, expression 310 
and activation of several cell signaling proteins in TAMs in hypoxia were examined. Twenty-311 
four hours treatment of TAMs under hypoxia caused the increase of adenosine 5‘-312 
monophosphate-activated protein kinase (p-AMPK), PI3K, phosphorylated AKT, hypoxia 313 
inducible factor-1α (HIF-1α) and intranuclear transfer of nuclear factor kappa-B (NF-κB) (Fig. 314 
5A and 5B). The presence of AMPK inhibitor compound C or PI3K inhibitor LY294002 315 
prevented the upregulation of galectin-3 in TAMs under hypoxia, but not under normoxic 316 




expression under both normoxia and hypoxia. Interestingly, the presence of HIF-1α inhibitor 318 
2ME2 increased the expression of galectin-3 in normoxia but not in hypoxia (Fig. 5C). Together, 319 
these results suggest that upregulation of galectin-3 in TAMs in hypoxia likely involves in 320 
activation of AMPK, PI3K and NF-κB signaling pathways. 321 
The involvement of AMPK activation in the regulation of galectin-3 expression seems to be 322 
supported by the discovery that the presence of AMPK activator, AICAR, promoted galectin-3 323 
expression in TAMs in normoxia (Fig. 5D). However, the presence of another AMPK activator 324 
metformin suppressed galectin-3 expression in TAMs in hypoxia (Fig. 5E), to the same extent 325 
as AMPK inhibitor compound C (Fig. 5D and 5E). This suggests the involvement of AMPK in 326 
the regulation of TAMs-mediated galectin-3 expression in hypoxia may be complex. Giving the 327 
opposite effects of AICAR and metformin have been shown previously to regulate intracellular 328 
reactive oxygen species (ROS) level[13, 14], ROS might be involved in the complex actions of 329 
AMPK in regulation of galectin-3 expression in hypoxic TAMs.  330 
To test this possibility, ROS levels in TAMs were analyzed. It was found that hypoxic 331 
treatment led to a dramatic increase of ROS in TAMs which was inhibited by the presence of 332 
compound C, LY294002, and PDTC. The presence of HIF-1α inhibitor 2ME2 increased the 333 
ROS level in normoxia but not in hypoxia (Fig. 5F). The changes of these inhibitors on the ROS 334 
level in TAMs were paralleled with the changes of galectin-3 levels (Fig. 5C). This suggested 335 
that the ROS may indeed be involved in the regulation of galectin-3 expression in TAMs in 336 
hypoxia. This conclusion was supported by the discoveries that treatment on TAMs with pro-337 
oxidant rosup in normoxia increased galectin-3 expression while treatment with ROS inhibitor 338 
NAC downregulated galectin-3 expression, and treatment with NAC reduced the increase of 339 
galectin-3 expression induced by 2ME2 (Fig. 5G).  340 




relationship of ROS on galectin-3 with NF-κB expression. The presence of compound C, 342 
LY294002, PDTC and NAC, which could all inhibit ROS generation in hypoxic TAMs, reduced 343 
the increase of NF-κB expression in TAMs caused by hypoxia. HIF-1α inhibitor 2ME2 344 
increased NF-κB of TAMs in normaxia. And NAC reduced the upregulation of NF-κB by 2ME2 345 
in normaxia (Fig. 5H). The effects of these inhibitors on NF-κB level were paralleled with the 346 
changes of galectin-3 mRNA expression. These findings indicate that ROS-associated 347 
upregulation of galectin-3 expression in TAMs under hypoxia is related to nuclear accumulation 348 
of NF-κB. 349 
 350 
3.6 Hypoxia-induced galectin-3 secretion promotes tumor metastasis and angiogenesis in 351 
vivo 352 
The effect of hypoxia on galectin-3expression in TAMs was further assessed in vivo in a 4T1-353 
luc orthotopic syngeneic mouse model of mammary adenocarcinoma. After 21 consecutive 354 
treatments with 8% O2 for 6 h/day (hypoxia group), the expressions of CD68 (M2 marker) and 355 
galectin-3 in tumor tissue were significantly increased in comparison to that in the control mice 356 
treated with 21% O2 (normoxia control group) (Fig. 6A), indicating that hypoxia induces 357 
macrophage tumor infiltration and galectin-3 secretion. It was found that the expression of 358 
CD31 (vascular endothelial cell marker) in tumor were also significantly increased in the 359 
hypoxia group (mice exposure to 8% O2) in comparison to the normoxia group (exposure to 360 
21% O2) (Fig. 6B), suggesting increased of angiogenesis.  361 
Lung metastasis of 4T1-luc cells from mammary fat pad was significantly higher in the 362 
hypoxia group than in the normoxia group assessed by an in vivo imaging system (Fig. 6C). 363 




metastasis of 4T1-luc cells and reduced the CD31 expression (Fig. 6B and 6C). Administration 365 
of liposomal clodronate (CL), which can deplete the macrophage[15], also inhibited the lung 366 
metastasis of 4T1-luc cells. The level of serum galectin-3 in the hypoxia group was significantly 367 
higher in comparison to the normaxia group (Fig. 6D). Administration of MCP or liposomal 368 
clodronate both reduced the serum galectin-3 level in the hypoxic mice. Together, these results 369 
suggest that hypoxia promotes TAMs tumor infiltration and secretion of galectin-3 and 370 
increases metastasis of breast cancer. 371 
 372 
3.7 Galectin-3 involves in the hypoxia aggravation and macrophage infiltration induced 373 
by antiangiogenic agents 374 
It has been reported that the antiangiogenic drug sorafenib promotes infiltration of TAMs, 375 
and its combination use with macrophage-depletion agent CL, can synergistically inhibit 376 
angiogenesis and lung metastasis[14]. We found that administration of sorafenib (15 mg/kg/day) 377 
for 3 weeks significantly reduced lung metastasis of breast cancer MDA-MB-231-luc cells in 378 
nude mice. Administration of CL (10 μL/g/weeks) with sorafenib significantly enhanced the 379 
inhibitory effects of sorafenib on tumor metastasis (Fig. 7A). Moreover, the serum level of 380 
galectin-3 in sorafenib treated group was significantly elevated in comparison to control group, 381 
which was reduced when sorafenib was used together with CL (Fig. 7B). These results indicate 382 
that the galectin-3 expression may also play an important role in the hypoxia aggravation of 383 
tumors under antiangiogenic drug treatment. 384 
Effect of bevacizumab, another antiangiogenic agent that has been reported to aggravate 385 
hypoxia and promote macrophage infiltration in tumor[16], was also assessed on galectin-3 386 




bevacizumab (5 mg/kg/week) with MCP (0.5 μL/g/day) for 3 weeks significantly enhanced the 388 
inhibitory effects of bevacizumab on tumor progression (Fig. 7C, 7D and 7F) and markedly 389 
decreased lung metastasis compared with mice treated with bevacizumab alone (Fig. 7G). 390 
Application of bevacizumab induced a significant increase of hypoxic area (evident of 391 
hypoxyprobe-1 expression) and intratumoral infiltration (CD68 expression) of TAMs (Fig. 7H), 392 
accompanied with an elevation of galectin-3 expression (Fig. 7I). Bevacizumab in combination 393 
with MCP also reduced angiogenesis (revealed by an increase of CD31) in mice (Fig. 7J). 394 
Moreover, serum level of galectin-3 in the bevacizumab treated mice was significantly elevated 395 
in comparison to that in the control mice, which was inhibited in the group with bevacizumab 396 
and MCP (Fig.7E). These results indicate the bevacizumab-induced increase of hypoxia and 397 
macrophages tumor infiltration was associated with the upregulation of galecin-3 expression. 398 
4. Discussion 399 
Recently, TAMs has drawn significant attention as a potential cancer therapeutic target. 400 
However, current TAMs-targeted therapies have not yet been widely accepted in clinical 401 
practice because of severe adverse reaction or low specificity[17]. Further development in this 402 
area may require new molecular targets. The report in this study showed that macrophages 403 
treated by IL-4/IL-13 or by CM from MDA-MB-231 cells both lead macrophages 404 
differentiation into M2 type and promote proliferation, invasion migration and angiogenesis of 405 
human breast cancer MDA-MB-231 cells under hypoxia in vitro and in vivo. These effects were 406 
shown to be closely linked with upregulation of galectin-3 expression and secretion by TAMs. 407 
It was found in this study that the presence of galectin-3 inhibitors lactose or MCP, or siRNA 408 
suppression of galectin-3 expression in TAMs could all inhibit TAMs-mediated promotion of 409 
the tumor cell behaviors in hypoxia. This indicates that both extracellular and intracellular 410 




with early studies showing galectin-3 upregulation during progression of prostate carcinoma, 412 
endometrial cancer, and colon cancer[18] and promoted tumor cell migration and 413 
angiogenesis[6, 19]. Interestingly, galectin-3 in hypoxia was also seen to enhance VEGFA 414 
secretion and glucose consumption in TAMs. This suggests that TAMs-associated increase of 415 
galectin-3 expression in hypoxia may play a role in TAMs metabolic reprogram, consequently 416 
altering TAMs functional phenotypes, such as polarization, secretion ability.  417 
It was found here that the expression of NF-κB, HIF-1α, AMPK and PI3K/AKT signaling 418 
were altered in TAMs in response to hypoxia. Change of these signaling proteins and a few 419 
others such as p53, homeodomain-interacting protein kinase 2, runt-related protein family and 420 
PI3K signaling pathways, have been reported previously to be associated with galectin-3 421 
expression[20, 21]. We observed in this study that the expression or phosphorylation of NF-κB, 422 
HIF-1α, AMPK and PI3K in TAMs and TAMs-associated galectin-3 expression was increased 423 
under hypoxia, and these changes were inhibited by inhibitors to NF-κB, AMPK, and PI3K and 424 
was correlated with changes of intracellular ROS levels.  425 
ROS, generated by Mitochondria in response to cellular stress such as hypoxia, acts as a 426 
second messenger to mediate cell actions, including promotion of cell survival, shifting 427 
metabolism to increased glycolysis, and activating angiogenesis, etc. by triggering downstream 428 
transcriptional signals[22, 23]. The present study showed that the presence of ROS inhibitors 429 
compound C, LY294002, PDTC and 2ME2 inhibited ROS production and downregulated 430 
galectin-3 expression of TAMs. This suggests a possible link between ROS production and 431 
galectin-3 expression in TAMs in hypoxia. Early studies have reported that hypoxia induces 432 
ROS production, leading to the stabilization of transcription factors HIF-1α and NF-κB 433 
nucleation in macrophage[24, 25]. Both HIF-1α and NF-κB transcription factors are reported 434 




participate in the regulation of galectin-3 transcription through activating HIF-1α or NF-κB. 436 
However, although HIF-1α expression was elevated in hypoxic TAMs, HIF-1α inhibitor 2ME2 437 
did not show any effect on galectin-3 expression in hypoxia. It instead increased galectin-3 438 
expression in normoxia, which correlated with changes of intracellular ROS levels. Early 439 
studies have reported that hybrid glioma cells treated with hypoxia did not affect galectin-3 440 
expression with or without HIF-1α inhibitor (2ME2), although HIF-1α accumulated in the cell 441 
nuclei[28]. Based on these early studies and our observation in this study, we deduce that HIF-442 
1α may not be a transcription factor involved in galectin-3 expression in hypoxic TAMs.  443 
The fact that NF-κB nucleation was induced in TAMs by hypoxia and the effects of inhibitors 444 
(including compound C, LY29002, 2ME2, rosup and NAC) on NF-κB were paralleled by the 445 
above changes of the mRNA expression of galectin-3 indicates that NF-κB is critically involved 446 
at transcription level in galectin-3 expression in TAMs in hypoxia, possibly through ROS 447 
generation. 448 
In our in vivo 4T1-luc orthotopic syngeneic mouse model of mammary adenocarcinoma and 449 
tail vein injection of MDA-MB-231 cells metastasis model, hypoxia showed to enhance TAMs 450 
tumor infiltration and galectin-3 expression, leading to increased metastasis. This metastasis-451 
promoting effect could be inhibited by administration of galectin-3 inhibitor MCP or 452 
macrophage depletion-agent clodronate-liposome (CL). MCP is a group of polysaccharides 453 
produced from citrus pectin. It is an effective galectin-3 inhibitor and showed in several early 454 
studies to effectively inhibit galectin-3-mediated tumor growth and metastasis, in vitro and/or 455 
in vivo, of prostate carcinoma, colon carcinoma, breast carcinoma, melanoma, multiple 456 
myeloma, and hemangiosarcoma[29, 30]. CL is commonly used to eliminate macrophage 457 
populations. Early studies have reported that depletion of macrophages by CL significantly 458 




lung metastasis of liver cancer[31]. It was found in this study that the growth inhibition and 460 
galectin-3 secretion produced by the anti-angiogenesis agents sorafenib or bevacizumab[14, 16] 461 
was reduced by administration of macrophage depletion-agent CL or galectin-3 binding 462 
inhibitor MCP. This suggests that galectin-3 may be involved in TAMs infiltration induced by 463 
anti-angiogenesis agents such as sorafenib or bevacizumab, thus a potential target in improving 464 
anti-angiogenic therapies. 465 
In conclusion, our in vitro and in vivo investigation suggests that the upregulation of galectin-466 
3 expression and secretion in TAMs is an important mechanism of TAMs-mediated promotion 467 
of tumor growth and metastasis in the tumor hypoxic microenvironment. The increased 468 
expression of galectin-3 is associated with an increase of intracellular ROS generation via 469 
activation of NF-κB nucleation. The upregulation of galectin-3 expression also enhances 470 
glucose consumption and VEGFA secretion by TAMs and promote angiogenesis under hypoxia. 471 
Moreover, galectin-3 inhibitors MCP could enhance the anti-tumor effects of anti-angiogenesis 472 
agents by inhibiting TAMs infiltration and tumor-promoting effects of TAMs in vitro and in 473 
vivo. Targeting the actions of galectin-3 in TAMs may therefore be a potential therapeutic 474 
strategy for cancer treatment.  475 
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Figure legends 585 
Fig. 1. TAMs promote proliferation, invasion and migration of MDA-MB-231, and tube 586 
formation of HUVECs under hypoxia. (A) Expressions of M2 markers CD163 and CD68 on 587 
the surface of THP-1, M2 and TAM cells were analyzed by flow cytometry. (B) M2 markers 588 
(IL-1R and IL-10) and M1 markers (NOS2 and IL-12) in the THP-1, M2 and TAMs were 589 
measured by RT-PCR. (C) Representative images (magnification, 200×, bar = 100 μm) show 590 
tube structures of HUVECs in responses to CM of M2 or TAMs in hypoxia for 6 h. (D) 591 
Following treatment with CM of M2 or TAMs for 24 h, cell proliferation of MDA-MB-231 was 592 
determined by MTT assay. (E) After THP-1 cells were differentiated into M2 or TAMs and co-593 
cultured with MDA-MB-231 cells in 1% O2 environment for 24 h, invasion or migration of 594 
MDA-MB-231 cells in trans-wells were determined. Data are presented as the means ± S.E.M. 595 
from three separate experiments. *P< 0.05, **P<0.01, v.s. Control group. 596 
Fig. 2. Hypoxia induces the expression and secretion of galectin-3 by TAMs. Galectin-3 597 
expression at protein (A) and mRNA (B) levels in M2 and TAMs after treatment of the cells 598 
with sodium dithionite or cultured in 1% O2 was determined by Western blot or RT-PCR. (C) 599 
Effect of hypoxia on galectin-3 secretion from M2 or TAMs was determined by ELISA. (D) 600 
Confocal microscopy images of galectin-3 localization in TAMs after treatment of the cells with 601 
1% O2 for 24 h (magnification, 600×, bar = 33 μm). (E) Immunohistochemical staining of 602 
tumors from the 4T1-luc orthotopic syngeneic mouse model with antibodies against 603 
Hypoxyprobe, and galectin-3 (magnification, 100×, bar = 400 μm). Data are presented as the 604 
means ± S.E.M. from three separate experiments. *P< 0.05, **P<0.01, v.s. Control group 605 




migration/invasion of breast cancer cells.  The migration and invasion of MDA-MB-231 607 
cell were determined in transwell after co-incubation with M2 (A), or TAMs (B) pre-treated 608 
with siGal-3, 10 mM β-lactose or 0.1% MCP (C) for 24 h in hypoxia (magnification, 200×, bar 609 
= 100 μm). (C)The migration and invasion of MDA-MB-231 cell were determined in transwell 610 
after co-incubation with M2, or TAMs pre-treated with MCP for 24 h in hypoxia (magnification, 611 
200×, bar = 100 μm). (D) Migration and invasion of MDA-MB-231cells were determined in 612 
transwells after co-incubation with M2 or TAMs pretreated with siGal-3 for 24 h in normoxia. 613 
(E) Cell proliferation of MDA-MB-231 after 24 h treatment with CM of TAMs in exposure to 614 
siGal-3 under hypoxia was determined by MTT assay. (F) Survival of M2 or TAMs in cell 615 
response to treatment of galectin-3 siRNA in hypoxia for 24 h was determined by MTT assay. 616 
(G) Glucose consumption of M2 or TAMs treated with or without galectin-3 siRNA under 617 
normoxia and hypoxia was determined by Glucose Assay. (H, I) Secretion of galectin-3 and 618 
VEGFA by M2 or TAMs treated without or with galectin-3 siRNA were measured by ELISA. 619 
Data are presented as the means ± S.E.M. from three separate experiments. *P<0.05, **P<0.01 620 
v.s. Scrambled siRNA; ∆P<0.05, ∆∆P<0.01 v.s. β-lactose + galectin-3; #P<0.05, ##P<0.01 v.s. 621 
Hypoxia. 622 
Fig. 4. Galectin-3 secretion by TAMs promotes angiogenesis and vascular mimicry under 623 
hypoxia. Representative images (magnification, 200×, bar = 100 μm) show vascular mimicry 624 
of MDA-MB-231 cells (A) or tube formation of HUVECs (B) after 6 h incubation of the cells 625 
with CM from hypoxic or normoxia (C) TAMs. (D) Representative images show HUVECs tube 626 
structures after 6 h incubation with MCP or CM from hypoxic TAMs. (E) Cell proliferation of 627 
HUVECs after 24 h treatment with CM of TAMs in exposure to siGal-3 under hypoxia was 628 
determined by MTT assay. (F) Cell migration and invasion of HUVECs was determined in 629 




hypoxia (magnification, 200×, bar = 100 μm). Data are presented as the means ± S.E.M. from 631 
three separate experiments. *P<0.05, **P<0.01, v.s. Scrambled siRNA; ∆P<0.05, ∆∆P<0.01 v.s. 632 
β-lactose + galectin-3. 633 
Fig. 5. Upregulation of galectin-3 in TAMs under hypoxia is dependent on NF-κB via ROS. 634 
(A) Expression of galectin-3, AMPK, PI3K and HIF-1α in hypoxic TAMs were analyzed by 635 
Western blot. (B) The level of NF-κB in hypoxic TAMs were assessed by immunofluorescence 636 
(magnification, 100×, bar = 200 μm). (C) Effects of PDTC (10 μM, pretreatment for 1 h), 637 
LY294002 (0.5 μM, pretreatment for 1 h), compound C (4 μM, pretreatment for 1 h) and 2ME2 638 
(10 μM, pretreatment for 0.5 h) on mRNA expression of galectin-3 in TAMs under hypoxia or 639 
normoxia were determined by RT-PCR.  (D, E) The protein expression of galectin-3 in TAMs 640 
in hypoxia pretreated with metformin (5 mM) or AICAR (1 mM) for 1h was assessed by 641 
Western blot. (F) Level of ROS in hypoxic TAMs pretreated with PDTC, LY294002, compound 642 
C, 2ME2 and NAC were analyzed by immunofluorescence (magnification, 100×, bar = 200 643 
μm). (G) Effects of rosup (50 mg/ml, pretreatment for 1 h), NAC (10 nM, pretreatment for 1 h) 644 
on galectin-3 mRNA expression in TAMs were analyzed by RT-PCR. (H) NF-κB in TAMs 645 
pretreated with LY294002, compound C, 2ME2 and NAC was analyzed by 646 
immunofluorescence. Data are presented as the means ± S.E.M. from three separate 647 
experiments. *P<0.05, **P<0.01 v.s. Normoxia control; #P<0.05, ##P<0.01 v.s. Hypoxia control. 648 
Fig. 6. Hypoxia induces galectin-3 secretion and that promotes tumor metastasis and 649 
angiogenesis in vivo. Balb/c mice were injected with 5 × 105 4T1-luc cells into the mammary 650 
fat pad under #3 mammary gland. Mice were daily treated with 8% O2 for 6 h, with or without 651 
intratumoral injection of 2% MCP (0.5 μL/g/day) for 21 days. (A, B) Expressions of CD68, 652 
galectin-3 and CD31 in tumor tissues were analyzed by immunofluorescence. (B)Expression of 653 




breast cancer cells from mammary fat pad was recorded using an in vivo imaging system (n = 655 
5). (D) Serum galectin-3 level in mice was detected by ELISA. All data are presented as means 656 
± SD, n = 5, *P<0.05 v.s. Normoxia control mice; #P<0.05 v.s. Hypoxia control mice.  657 
Fig. 7. Galectin-3 is involved in hypoxia aggravation and macrophage infiltration induced 658 
by antiangiogenic agents. (A) Lung metastasis in nude mice of breast cancer was established 659 
by intravenous injection of MDA-MB-231-luc cells by tail vein. The lung metastasis was 660 
assessed using an in vivo imaging system. (B) Serum concentration of galectin-3 in the mice 661 
was measured by ELISA. (C, D) Balb/c mice were injected with 5 × 105 4T1-luc cells into the 662 
mammary fat pad under #3 mammary gland. The body weight (C) and tumor volume (D) of 663 
mice were recorded every 3 days for 21 days. (E) Serum concentration of galectin-3 in mice 664 
was measured by ELISA. (F, G) The orthotopic growth and lung metastasis was analyzed using 665 
an in vivo imaging system (n = 5). Hypoxia area and macrophage infiltration (H) and galectin-666 
3 expression (I) in tumor sections were analyzed by immunofluorescence. (J) Expression of 667 
CD31 in tumor tissues was analyzed by Immunohistochemistry. All data are presented as means 668 
± SD, n = 5, *P<0.05, **P<0.01 v.s. Hypoxia control group; #P<0.05, ##P<0.01 v.s. Sorafenib 669 
group or Bevacizumab group. 670 
 671 




































Graphic abstract 687 
 
38 
 
 688 
